An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

NCT02365597 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

239

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Cancer

Interventions

DRUG: Erdafitinib
DRUG: Midazolam
DRUG: Metformin

Sponsor

Janssen Research & Development, LLC